If you’ve been living with bipolar disorder for more than a few years, there’s a good chance you’ve been prescribed an antidepressant at some point — possibly before your bipolar diagnosis was clear, possibly by a provider who didn’t specialize in mood disorders, possibly during a depressive episode that felt indistinguishable from unipolar depression. And if that antidepressant made things feel more volatile instead of better, you’re not imagining things.
Antidepressants and bipolar disorder are one of the most misunderstood combinations in psychiatric care. This article explains what the evidence actually shows — why these medications can destabilize mood in some people with bipolar disorder, who is at higher risk, what the current treatment guidelines recommend instead, and what it means for your care.
If you’ve had confusing experiences with antidepressants and are wondering whether your care plan is actually designed for bipolar, get started with Sway Health — a consult with a bipolar-specialized clinician is a low-commitment way to get a second opinion.
At a Glance
- Research estimates that 50–60% of people with bipolar disorder are prescribed antidepressants, despite significant concerns about their safety in this population.
- Antidepressants can trigger a switch from depression into mania or hypomania — a phenomenon called Treatment-Emergent Affective Switch (TEAS) — and may accelerate episode cycling in some people.
- The risk is highest with tricyclic antidepressants, bipolar I disorder, rapid cycling, and mixed features — but it exists across antidepressant types.
- Current international guidelines do not recommend antidepressant monotherapy for bipolar depression. First-line options include mood stabilizers and specific atypical antipsychotics.
- If you’ve been prescribed an antidepressant without a mood stabilizer, that doesn’t mean something went wrong with you — it may mean your care wasn’t designed with bipolar specifically in mind.
Why Bipolar Depression Gets Treated Like Unipolar Depression
Here’s the core problem: bipolar disorder and unipolar depression can look nearly identical when someone is in a depressive episode.
The symptoms overlap substantially — persistent low mood, loss of interest, sleep disruption, fatigue, difficulty concentrating, hopelessness. There’s no blood test that distinguishes them. Without a careful history, the correct diagnosis can be easy to miss. According to a review published in the Journal of the American Association of Nurse Practitioners, up to 64% of clinical encounters for depression occur in primary care — settings where bipolar-specific assessment is often not the default.
The result is that many people with bipolar disorder spend years being treated for unipolar depression before the correct diagnosis is made. One study found that an average of 7.5 years elapsed before bipolar disorder was identified in a cohort of patients. During that time, antidepressants are often the treatment of choice — because they’re the standard of care for unipolar depression, and they look like the right answer for the presenting problem.
But bipolar depression is not the same as unipolar depression. It requires a different clinical approach. And when it’s treated with an antidepressant alone — without a mood stabilizer in place — the consequences for some people can be significant.
The Misdiagnosis Gap and Its Consequences
Research has found that misdiagnosed bipolar patients received treatment regimens involving overuse of antidepressants and underuse of potentially effective medications. This isn’t a commentary on individual providers — it’s a structural problem in how mood disorders are assessed and treated in generalist settings. The solution is bipolar-specialized care that knows what to look for.
If this matches your experience — years of antidepressants, a late bipolar diagnosis, a sense that something never quite worked — you’re not alone, and you didn’t do anything wrong.
What Are Antidepressants, and Why Are They Still Prescribed for Bipolar?
Antidepressants — a category that includes selective serotonin reuptake inhibitors (SSRIs) like sertraline and fluoxetine, serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine, and older tricyclic antidepressants (TCAs) — work primarily by modulating monoamine neurotransmitters in the brain. In unipolar depression, this mechanism is often effective at lifting the depressive state.
The reason they’re still prescribed in bipolar disorder, despite ongoing controversy, is complex:
- Depressive episodes are far more common and often more debilitating than manic or hypomanic episodes. Research shows people with bipolar disorder spend approximately three times as many weeks in depressive states as in manic or hypomanic states.
- There are relatively few medications approved specifically for bipolar depression. According to NAMI, only quetiapine and the combination of olanzapine and fluoxetine (Symbyax) are FDA-approved for bipolar depression.
- Some patients and clinicians report that antidepressants do appear to help certain subgroups, particularly those with bipolar II.
- Antidepressants are widely available, familiar to prescribers, and covered by insurance.
A 2025 review published in PMC estimates that 50–60% of people with bipolar disorder are currently prescribed antidepressants — suggesting that actual prescribing practice is substantially ahead of what clinical guidelines recommend.
If you’re one of those people, this isn’t a judgment of you or even necessarily of your prescriber. But it’s worth understanding the risks involved.
The Specific Risks: What Can Go Wrong
Treatment-Emergent Affective Switch (TEAS)
The most significant risk of antidepressant use in bipolar disorder is what clinicians call Treatment-Emergent Affective Switch (TEAS) — a shift from a depressive state into mania, hypomania, or a mixed state, triggered by antidepressant treatment.
TEAS is not the same as a natural mood episode. It’s a medication-induced transition, and it can be disorienting and destabilizing precisely because it follows closely on treatment. Someone who begins an antidepressant for what appears to be depression may experience a period of elevated energy, decreased need for sleep, impulsivity, or irritability within weeks — sometimes mistaken for the depression “lifting,” until it becomes clear something more is happening.
As noted in a review of the evidence, patients treated with antidepressants that aren’t appropriate for their condition “are known to induce mania and provoke rapid cycling” when used improperly. The 2024 review in the American Journal of Psychiatry notes that antidepressant monotherapy is not endorsed as first-line for acute bipolar depression, in part because of this risk.
Rapid Cycling
Beyond the acute risk of TEAS, there’s evidence that antidepressants can contribute to rapid cycling — defined as four or more mood episodes in a 12-month period. Rapid cycling is associated with a more severe illness course, greater functional impairment, and more difficult treatment.
The landmark STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder) trial — a large, NIMH-funded study — included a randomized clinical trial specifically examining the effect of modern antidepressants on rapid cycling. Its findings showed that antidepressants worsen the rapid-cycling course in bipolar depression, providing the most rigorous evidence to date on this specific concern.
Mixed Features and Symptom Destabilization
Some people experience neither clean mania nor clean depression, but mixed features — simultaneous depression and manic symptoms, such as severe anxiety, restlessness, and hopelessness occurring together. Antidepressant use in the context of mixed features is particularly concerning, as research suggests it can intensify or prolong the mixed state rather than resolving the depressive component.
Key Takeaway: TEAS, rapid cycling induction, and mixed feature exacerbation are all documented risks of antidepressant use in bipolar disorder — especially without concurrent mood stabilization.
Who Is at Higher Risk?
Not everyone with bipolar disorder responds the same way to antidepressants. The evidence suggests certain clinical profiles carry substantially higher risk of adverse outcomes:
- Bipolar I vs. Bipolar II: The risk of TEAS is higher in bipolar I disorder compared to bipolar II, likely because the underlying mood instability is more pronounced.
- Rapid cycling history: Patients who already cycle rapidly are at significantly higher risk of further destabilization.
- Mixed features during a depressive episode: The presence of mixed features — irritability, agitation, racing thoughts alongside depression — is a significant risk factor for TEAS.
- Tricyclic antidepressants (TCAs): Older antidepressants in the TCA class carry the highest risk of switch compared to modern SSRIs and SNRIs. This is well-established in the literature.
- Antidepressant monotherapy (no mood stabilizer): Using an antidepressant without a concurrent mood stabilizer substantially increases risk across all antidepressant types.
- History of stimulant abuse: Research identifies this as an additional risk factor for TEAS.
This doesn’t mean that antidepressants are never appropriate in bipolar disorder. Some individuals — particularly those with bipolar II, longer depressive episodes, and stable mood otherwise — may do well with an antidepressant alongside a mood stabilizer, under careful monitoring. The clinical question is about the individual: their illness subtype, their episode history, and their risk profile.
That individual-level assessment is exactly what bipolar-specialized prescribers are trained to do. It’s also what distinguishes specialized care from generalist treatment.
If you’re uncertain about your own situation, explore bipolar treatment options to understand the full range of what’s available.
What the Guidelines Say
The major international guidelines are consistent on this point: antidepressant monotherapy is not recommended for bipolar depression, and antidepressants should be used cautiously and selectively even as adjunctive treatment.
The CANMAT/ISBD guidelines — developed by the Canadian Network for Mood and Anxiety Treatments and the International Society for Bipolar Disorders, and updated in 2023 — explicitly state that antidepressants should be discontinued in patients presenting with acute mania. Their ranking system for treatment recommendations accounts specifically for risk of treatment-emergent affective switch when placing medications into first-, second-, and third-line categories.
The American Psychiatric Association places mood stabilizers — lithium, valproate, lamotrigine — and atypical antipsychotics as the cornerstone of bipolar disorder treatment, with psychotherapy as an important adjunct.
The NIMH’s information on bipolar disorder similarly frames treatment around mood stabilizers and atypical antipsychotics for bipolar depression, not antidepressants.
First-Line Options for Bipolar Depression
Current evidence supports several alternatives to antidepressant monotherapy for treating the depressive phase of bipolar disorder:
- Quetiapine — One of the best-studied options for bipolar depression, with demonstrated efficacy in multiple controlled trials
- Lurasidone — Second-generation antipsychotic with solid RCT evidence for bipolar I depression
- Cariprazine — Approved for both bipolar depression and bipolar mania
- Lamotrigine — Mood stabilizer with particular efficacy for the depressive pole
- Lithium — Evidence for both maintenance and acute treatment of bipolar depression
This is where bipolar-specialized prescribing matters. A clinician trained in mood disorders knows these options, knows the evidence behind each, and knows how to weigh them against your specific episode history, risk factors, and life circumstances.
Key Takeaway: International guidelines don’t recommend antidepressant monotherapy for bipolar depression. If that’s your current treatment, it may be time to ask your care team why — or to seek a second opinion from a specialist.
What Bipolar-Specialized Prescribing Actually Looks Like
If you’ve been on antidepressants for bipolar disorder and experienced destabilization, or if you’ve been on an antidepressant for years with incomplete results, this is a conversation worth having with a specialist.
Bipolar-specialized prescribers approach medication differently. They:
- Take a detailed episode history to understand your specific illness pattern — how long your depressive phases last, whether you have mixed features, whether you’ve cycled rapidly
- Know the TEAS risk factors and factor them into prescribing decisions
- Prioritize mood stabilization as the foundation, adding other medications selectively around that base
- Monitor for signs of TEAS when any new medication is introduced
- Understand the difference between bipolar I, bipolar II, and cyclothymia, and why those distinctions matter for treatment
At Sway Health, this is the default way we approach care — not the specialized exception, but the standard. Every clinician is bipolar-specialized by training and selection.
If you’ve felt for a while that your medication regimen wasn’t built for bipolar specifically, you may be right. Learn more about bipolar depression and what specialized assessment looks like.
If this sounds like where you are — medication that’s never quite worked, destabilization you couldn’t explain, a sense that your prescriber was managing symptoms without fully understanding the condition — a consultation with a bipolar specialist is a low-cost, low-commitment step. You don’t have to switch providers to get a second opinion.
Frequently Asked Questions
Can antidepressants trigger mania in people with bipolar disorder?
Yes. This is called a Treatment-Emergent Affective Switch (TEAS) — a shift from depression into mania, hypomania, or mixed states triggered by antidepressant treatment. Research confirms this risk, and it’s one of the primary reasons current guidelines don’t recommend antidepressant monotherapy for bipolar depression. Risk is higher with tricyclics than with SSRIs, and higher in bipolar I than bipolar II.
Are SSRIs safer than other antidepressants for bipolar disorder?
SSRIs are generally considered lower risk for TEAS than older tricyclic antidepressants, but they’re not without risk. The evidence on SSRIs in bipolar disorder is mixed — some studies show benefit when combined with a mood stabilizer; others raise concerns about mood destabilization over time. No antidepressant is fully “safe” for bipolar disorder without appropriate mood stabilization in place. If you’re taking an SSRI, it matters whether you also have a mood stabilizer and whether your prescriber is monitoring for signs of destabilization.
Should I stop taking my antidepressant if I have bipolar disorder?
This is a question to work through with a qualified clinician — not something to change unilaterally. Stopping an antidepressant abruptly can cause discontinuation symptoms and can itself trigger a depressive episode. What matters is getting a careful review of your current regimen by someone who specializes in bipolar disorder, who can assess whether your current treatment plan is appropriate for your specific presentation. If you don’t have that kind of specialist in your corner, take a free bipolar disorder screening as a starting point.
What medications are actually approved for bipolar depression?
According to NAMI, only two medications are FDA-approved specifically for bipolar depression: quetiapine and the combination of olanzapine and fluoxetine (Symbyax). Additional medications including lurasidone, cariprazine, and lamotrigine have strong evidence for bipolar depression even without specific FDA approval for this indication. Lithium also has substantial evidence for bipolar depression.
Why do so many people with bipolar disorder end up on antidepressants if they’re not first-line?
Primarily because bipolar disorder is frequently misdiagnosed as unipolar depression, especially in primary care settings. Up to 64% of depression encounters occur in primary care, where bipolar-specific assessment isn’t always standard. When someone presents with depression and the clinician isn’t looking for bipolar, antidepressants are the default treatment. This is why specialized care — from providers trained to recognize and properly treat bipolar disorder — makes such a difference.
Moving Forward
If you’ve read this and recognized pieces of your own experience — years of antidepressants that never fully worked, episodes that seemed to escalate with treatment, a sense that no one was looking at the full picture — that recognition is worth something.
Bipolar disorder requires a different clinical approach than depression, and that approach starts with correct diagnosis and specialists who understand the distinction. Our guide to medication for bipolar depression covers more about what evidence-based medication management for this condition actually looks like.
You’re not out of options. The treatment may not have been wrong because of something about you — it may have been wrong because it wasn’t designed for bipolar specifically. There’s a meaningful difference, and it’s worth exploring.
If you’re ready to see what bipolar-specialized care looks like, see a bipolar disorder specialist online through Sway Health — check your insurance coverage and book a consultation at your own pace. No pressure. Just a chance to see if the care you’ve been missing has been available all along.
